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Trastuzumab as adjuvant treatment for early stage  
HER2-positive breast cancer — a 10 year history
Barbara Radecka
Overexpression of the receptor for human epidermal growth factor type 2 (HER2), or gene amplification for this receptor 
is observed in approx. 20–25% of breast cancer patients and is associated with a more aggressive course, a higher risk 
of recurrence and shorter survival. Trastuzumab, a monoclonal antibody, directed to the extracellular domain of the 
HER2 receptor, was introduced for the treatment of HER2-positive breast cancer in 1998, and its use has caused equal 
opportunities for patients with HER2-positive breast cancer and those with HER2-negative. In adjuvant treatment of 
early breast cancer the risk of recurrence is decreased and overall survival is prolonged. The results of international 
randomised studies, published more than 10 years ago, despite some controversies concerning optimal regimen and 
duration of treatment, almost immediately became the basis for a change in the standard of care. Currently we know 
that the optimal administration of trastuzumab is concurrent with taxane-based chemotherapy, but it should not be 
added to anthracyclines. Long-term observation of the patient population treated in these trials has shown that the 
introduction of trastuzumab to clinical practice has changed the natural history of HER2-positive early breast cancer. 
The benefit from this treatment lasts for many years.
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Introduction 
The human epidermal growth factor 2 receptor (HER 2) 
was identified in 1984. It soon became a significant thera-
peutic target in breast cancer and remained so for the next 
30 years. Its overexpression or amplification of this receptor’s 
gene occurs in about 20–25% of breast cancer patients and 
is connected with a more aggressive course of the disease, 
a larger risk of recurrence and a shorter survival period [1–3].
Trastuzumab, a monoclonal antibody, directed at the 
extracellular domain of the HER2 receptor, has been studied 
since the early 90s. [4, 5]. Initially, its value was confirmed in 
the treatment of the advanced stage of the disease, which 
resulted in its approval for the market in the USA in 1998. In 
2001, Slamon et al published the results of the third phase 
trail, in which they proved that adding Trastuzumab to first 
line chemotherapy allows for the increase of the median 
progression-free survival period (PFS) from 4.6 to 7.4 months 
[4]. From 2000 onwards, the value of trastuzumab in the 
treatment of early stages of breast cancer was assessed. 
Between 2000–2001, 4 large randomised international trials 
(HERA, NSABP-B31, NCCTG-N9831 and BCIRG 006) as well as 
2 smaller ones — Finnish (FinHer) and French (PACS-04) with 
a random selection, were started with almost 12 thousand 
patients enrolled [6–12].
In spite of the many differences concerning the con-
struction of a trial, patient population, the chemotherapy 
regimens applied, methods of dosing and the duration of 
Trastuzumab treatment, all these studies proved there were 
some benefits in the application of the antibody. The first 
data analyses pointed to a 30% decrease in the risk of death 
and a decrease in recurrence risk varying between 39–52%. 
These results have been the most significant progress since 
the introduction of Tamoxifen to the treatment of breast 
cancer and have provided grounds for the change of the 
standard of adjuvant therapy [13]. All the above studies 
have undergone subsequent analyses and their long-term 
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outcomes confirm the benefits of the application of Tras-
tuzumab in adjuvant therapy of early HER2-positive breast 
cancer. The studies evaluated various methods of combining 
Trastuzumab with chemotherapy. 
Studies overview
The primary endpoint of the referred international ran-
domised trials was the disease-free survival period (DFS), 
and in the trials: NSABP-B31, NCCTG-N9831, additionally 
it was the overall survival (OS). Table I presents the most 
significant data concerning all the 4 above-mentioned trails.
The objective of the HERA study was to assess the value 
of one and two-year therapy with Trastuzumab added to 
chemotherapy in comparison with chemotherapy alone in 
patients with early HER2-positive breast cancer after surgical 
treatment and standard chemotherapy (induction, adjuvant 
or induction and adjuvant chemotherapy). Both the patients 
with metastases (68%), and without metastases (32%) in the 
inguinal lymph nodes were included in the study; however 
in the latter group, the primary tumour size, as evaluated in 
the post-operative sample (pT) had to be larger than 1 cm. 
Various chemotherapy regimens were accepted which al-
lowed for carrying out the study in many countries (Tab. II). 
The first results (with the median observation period of 12 
months) comprised the comparison of the combination 
of chemotherapy with Trastuzumab administered for one 
year with chemotherapy solely. Some improvement in DFS 
was observed — a 46% decrease in the risk of tan occur-
rence of an event in the group of patients with combined 
treatment (HR 0.54, 95% CI 0.43–0.67, p < 0.0001) [6]. The 
results were confirmed in another analysis performed after 
almost 2 years of observation; The HR ratio was then 0.64 
(Tab. III) [7]. Also the benefits in the combined therapy for 
overall survival were proven (HR 0.66, 95% CI 0.47–0.91, p = 
0.0115). The results of the first analysis led to the decision to 
enable patients treated with chemotherapy solely to start 
therapy with Trastuzumab (cross-over). Such an opportu-
nity was used by 884 out of 1698 patients (52%) initially 
treated Trastuzumab. The therapy with Trastuzumab was 
commenced in the cross-over cohort within a varied time 
period from randomisation (median: 22.8 months, scope 
4.5–52.7 months) and, in spite of these differences, also 
in this group there was some significant decrease in the 
risk of recurrence observed in comparison with the group 
of patients who were not receiving Trastuzumab (HR 0.68, 
95% CI 0.51–0.90; p = 0.0077). The results of the HERA trial 
provided grounds for the registration of Trastuzumab for 
adjuvant therapy. 
American trials (NSABP-B31, NCCTG-N9831) had a slight-
ly different construction with respect to the selection of 
adjuvant chemotherapy. In all the patients, the sequential 
chemotherapy with anthracyclines (doxorubicin + cyclo-
phosphamide, AC) and taxoids (paclitaxel) was appliedThe 
regimens differed from each other with regards to dosage 
and the frequency of paclitaxel administration, comprising 
the regimes of administration every three weeks and every 
one week. The trial construction, however, concerning the 
comparison of the effectiveness and safety of chemotherapy 
alone with the Trastuzumab combined treatment was simi-
lar. Although the first of the trials had two arms whilst the 
second had three study arms, arm 1 and 2 in the NSABP-
B31 trial and arm A and C in the NCCTG-N9831 trial were 
similar (Tab. II). That is why the National Cancer Institute 
(NCI) in the USA approved a joint evaluation of the results 
of these two studies, excluding arm B [9]. The first analysis 
(after the observation period with a 2-year median) showed 
a significant improvement of DFS (HR 0.48; 95% CI 0.39–0.59, 
p < 0.0001) in the group of patients treated with Trastu-
zumab. In this population a 33% decrease in mortality risk 
was also observed (HR 0.67; 95% CI 0.48–0.93, p = 0.015) [8]. 
After almost one year, the benefits remained on a similar 
level (Tab. III) [9]. It must be observed that the results of arm 
B of the NCCTG-N9831 trial were not published (sequential 
treatment). 
The objective of the BCIRG 006 study was to evaluate the 
value of Trastuzumab in combination with 2 types of taxoids 
therapy — with anthracyclines (AC, and then docetaxel 
+ trastuzumab) and without anthracyclines (docetaxel + 
carboplatin + trastuzumab – DCbT, described also as TCH). 
This was the outcome of a search for methods of decreasing 
Table I. Characteristics of the international studies evaluating trastuzumab in adjuvant therapy 
Study HERA B31 and N9831 BCIRG 006
Number of subjects 
Planned 5102 2043 and 2766 3222
Included 3401 1736 and 1615 3222
Age of the subjects (years median) 51 51 52
The rate of the subjects without metastases to axillary lymph nodes 32 5.7 29
The number of subjects receiving taxoids 26 100 100
Primary end-point DFS OS/DFS DFS
DFS — disease-free survival; OS — overall survival
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the risk of cardiotoxicity while maintaining the maximum ef-
fectiveness of the adjuvant therapy. The preliminary results 
of the study (an observation period median of 23 months) 
showed a significant improvement in the progression free 
survival period in both arms with (hazard ratio for DFS, [HR], 
0.49; 95% CI 0.37–0.65, p < 0.0001 for the arm with anthracy-
clines and HR 0.61; 95% CI 0.47–0.79, p = 0.0002 for the arm 
with anthracyclines), whilst the difference between the arm 
with Trastuzumab, though clearly seen, was not significant 
(p = 0.16) [14]. Another analysis, after a one year observation 
period confirmed earlier results, yet, similarly as in the case 
of the HERA study, the hazard ratios were slightly higher 
(Tab. III) [15]. In accordance with the objective of the study, 
significant differences were observed in the incidence of 
cardiological events (a decrease of the ejection fraction by 
≥ 10% was observed in 17% patients in the arm combining 
doxorubicin and trastuzumab, 9% in the arm with doxoru-
bicin alone and 8% in the arm combining carboplatin and 
trastuzumab).
The FinHer study was initially planned with an objective 
to compare 2 regimens of adjuvant chemotherapy — 3 cy- 
cles of docetaxel every 3 weeks and 9 weekly doses of 
vinorelbine followed by 3 cycles of FE50C (5-fluorouracil + 
epirubicin 50 mg/m2 + cyclophosphamide) every 3 weeks 
in both arms. Out of 1010 patients included in the study, 
232 of them had a diagnosis of HER2-positive cancer. With 
regards to the available knowledge concerning the value of 
trastuzumab in the adjuvant treatment, these patients were 
additionally randomised, with an administration of 9 weekly 
doses of trastuzumab at the same time with docetaxel or 
vinorelbine or chemotherapy alone. A significant decrease 
in the risk of breast cancer recurrence was observed (median 
Table II. Therapy regimens
Study Arm Regimen
HERA
1 Standard chemotherapy Æ T every 3 weeks for 1 year
2 Standard chemotherapy Æ T every 3 weeks for 2 years
3 Standard chemotherapy
NSABP B-31
1 4 × AC every 3 weeks Æ 4 × Pct every 3 weeks
2 4 × AC every 3 weeks Æ 4 × Pct every 3 weeks + T every one week for a year
NCCTG N9831
A 4 × AC every 3 weeks Æ 12 × Pct every one week
B 4 × AC every 3 weeks Æ 12 × Pct every one week Æ T every one week for a year
C 4 × AC every 3 weeks Æ 12 × pPct + T every one week Æ 40 × T every one week
BCIRG 006
1 4 × AC every 3 weeks Æ 4 × Dct every 3 weeks
2 4 × AC every 3 weeks Æ 4 × Dct every 3 weeks + T for a year (with Dct every week and then every 3 weeks)
3 6 × DCb every 3 weeks + T for a year (with DCb every week and then every 3 weeks)
AC — doxorubicin + cyclophosphamide; Dct — docetaxel; DCb — docetaxel + carboplatin; Pct — paclitaxel; T — trastuzumab
Table III. Preliminary and long-term results of international studies evaluating trastuzumab in adjuvant therapy 
Study HERA B31 and N9831 BCIRG 006
ACÆDct+T DCb+T
Preliminary results DFS HR 0.64 0.48 0.61 0.67
(95% CI) (0.54–0.76) (0.39–0.59) (0.48–0.76) (0.54–0.83)
p value < 0.0001 < 0.00001 < 0.0001 0.0003
OS HR 0.66 0.65 0.59 0.66
(95% CI) (0.47–0.91) (0.51–0.84) (0.42–0.85) (0.47–0.93)
p value 0.0115 0.0007 0.004 0.0017
Median follow-up period (months) 23.5 34.8 36
Long-term results DFS HR 0.76 0.60 0.70 0.76
(95% CI) (0.68–0.86) (0.53–0.68) (0.60–0.83) (0.65–0.90)
p value < 0.0001 0.001 < 0.001 < 0.001
OS HR 0.74 0.63 0.64 0.76
(95% CI) (0.64–0.86) (0.54–0.73) (0.52–0.79) (0.62–0.93)
p value < 0.0001 0.001 < 0.001 0.0081
Median follow-up period (years) 11 8.4 10.3
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observation period: 3 years) under the influence of the ap-
plication of Trastuzumab (HR 0,46; p = 0,0078) [11]. 
The PACS-04 study comprising 528 patients (including 
those with axillary lymph nodes metastases), was the only 
study which did not show any significant reduction in dis-
ease recurrence in the patients receiving trastuzumab [12]. 
Nevertheless, in this study a 14% decrease in the recurrence 
risk was also observed (HR 0.66; p = 0.41) and an improve-
ment of the 3-year progression-free survival rate (78% in 
the group of patients treated with chemotherapy alone 
in comparison with 81% in the group with trastuzumab 
administered additionally).
Long-term study results
An integral element of the studies concerning adjuvant 
treatment is the long follow-up period, which provides re-
mote study results for evaluation. The long term results 
concern not only effectiveness, but also safety, which is 
especially important in the case of radical treatment. The 
data from the study concerning the efficiency of trastu-
zumab in the treatment of early breast cancer confirm that 
of 1698 patients treated ith the arm with chemotherapy 
alone, there is still a relative risk of recurrence (HR 0.76; 
95% CI 0.68–0.86, p < 0.0001) and of death (HR 0.74; 95% CI 
0.64–0.86, p < 0.0001) although the indicators are slightly 
lower than in earlier studies (Tab. III, Fig. 1a and 1b). This 
benefit is observed both in patients with the expression 
of steroid receptors and without them. The results of the 
Trastuzumab study, which was prolonged to 2 years, point 
to a lack of additional benefit in such methods (DFS – HR 
0.77; 95% CI 0.69–0.87, p < 0.0001 and OS — HR 0.72; 95% 
CI 0.62–0.83, p < 0.0001). This confirms the observation 
that the optimum duration of the adjuvant treatment with 
trastuzumab is 1 year.
The result of long-term joint analysis (median observa-
tion period was 8.4 years) of the American studies (NSABP-
B31, NCCTG-N9831) also confirmed a permanent benefit in 
combining trastuzumab with adjuvant therapy (synchro-
nous administration of trastuzumab with taxoids following 
a previous anthracycline therapy). A relative improvement 
in theoverall survival of 37% was observed (HR 0.63; 95% 
CI 0.54–0.73; p = 0.001) and an increase in the 1 year sur-
Figure 1a. Long-term study results: HERA — DFS [17]
trastuzumab provides equal chances for the patients with 
HER2-positive breast cancer and the patients with HER2-
-negative breast cancer [16].
A long-term (median period of 11 years) observation 
of the patients in the HERA study presented in December 
2015 at the San Antonio conference, point to a ongoing 
benefit in treatment with Trastuzumab [17]. In spite of 
the above-mentioned crossover, which took place after 
the first analysis in 2005 and included 884 subjects out 
vival rate from 75.2% with chemotherapy alone to 84% in 
the combined treatment with trastuzumab (Tab. III, Fig. 2a 
and 2b). A similar benefit was observed in disease free sur-
vival (HR 0.60; 95% CI 0.53–0.68, p = 0,001, an increase of 
the 10-year DFS rate DFS from 62.2% to 73.7% respective-
ly). Trastuzumab improved the treatment results in all the 
analysis subgroups, whereas synchronous administration 
of trastuzumab with taxoids is proven to be more effective 
than sequential treatment [18]. 
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Similar results were obtained within a long observa-
tion period (median observation period: 10.3 years) of the 
patients from the BCIRG 006 study. A significant improve-
ment of survival periods was observed (DFS and OS) in both 
study arms with combined therapy in comparison with 
chemotherapy alone [19]. In the arm with anthracyclines, 
for the disease free survival (ACÆDct+T) the obtained HR 
value was 0.70 (95%CI 0.60–0.83, p < 0.001), whilst in the arm 
without anthracyclines (DCbT) — HR 0.76 (95% CI 0.65–0.90, 
p < 0.001), and the rates were slightly lower than in the 
previous analysis (then it was 0.61 and 0.67 respectively, 
Table III, Figure 3a and 3b). Also a decrease in the relative 
risk by 36% was observed in the ACÆDct+T arm (HR 0.64; 
95%CI 0.52–0.79, p < 0.001) and by 24% in the DCbT arm 
(HR 0.76; 95% CI 0.62–0.93, p = 0. 0081). With regards to 
the survival rate, no significant differences between the 
two study arms were observed (with anthracyclines and 
without anthracyclines) and this concerns also the patients 
with a high risk of recurrence (metastases to more than 
3 axillary lymph nodes), which confirms the value of the 
DCbT regimen in the patients with u pN+. In the arm with 
anthracyclines, the incidence of congestive heart disease 
was five times higher (21 cases — 2.0% in comparison with 
4 cases — 0.4%; p = 0.0005) and also there was a twofold in-
crease in the incidence of the reduction of the left ventricular 
ejection fraction 2 (LVEF) above 10% (206 in comparison 
with 97 respectively; p < 0.0001). In the group of patients 
treated with chemotherapy alone, there were 8 cases of 
symptomatic heart failure (0.8%). The long term results of 
the BCIRG study suggest that in patients with early HER2- 
-positive breast cancer treated with adjuvant trastuzumab, 
chemotherapy without anthracyclines is not worse than 
with anthracyclines, as it brings about a much lower risk of 
cardiological complications.
The final results of the FinHer study were published in 
2009, after a follow-up period with the median period of 5.2 
years [20]. In the subgroup of patients with HER2-positive 
breast cancer, it was shown that the addition of trastuzumab 
(9 weekly doses) to chemotherapy decreased the relative 
risk of the cancer spreading by 35% in comparison with 
chemotherapy alone, yet this difference proved to be in-
significant — distant disease-free survival (DDFS); HR 0.65, 
95% CI 0.38–1.12, p = 0.12). In the subgroup analysis one 
significant advantage of the Dct+TÆFEC treatment over 
other arms was proven without increasing cardiotoxicity. 
Controversies
The differences in the treatment methods of the pre-
sented studies (the duration of the trastuzumab treatment, 
immediate or sequential combination of trastuzumab and 
taxoids) led to some controversies, the majority of which 
were resolved within the course of the follow-up or on the 
basis of additional studies.
In four large trials the treatment duration was empiri-
cally defined for 1 year. In the HERA study, the addition of 
an arm with a 2-year study period was intended to show 
whether the prolongation of the treatment with trastu-
zumab would increase the benefits in the use of this drug. 
Some shorter periods of trastuzumab were also studied. 
The first study of such a type was the FinHer trial conducted 
in Finland. The benefits in a 9-week treatment, observed 
in the initial results (in the subgroup receiving docetaxel 
Figure 1b. Long-term study results: HERA — OS [17]
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with trastuzumab, the share of the patients without distant 
metastases was significantly lower than in the group receiv-
ing chemotherapy alone, p = 0.029) were, for a few years, 
the subject of some controversies concerning the optimal 
duration of the treatment with trastuzumab. Some further 
studies comparing shorter and longer administration of 
the drug (PHARE, PERSEPHONE, Short-HER), as well as the 
long-term results of the 2-year long treatment in the HERA 
study allowed for the final determination of the standard 
treatment to be a 1-year duration therapy [21–24].
Figure 2a. Long-term study results: NSABP-B31, NCCTG-N9831 — DFS [18]
Figure 2b. Long-term study results: NSABP-B31, NCCTG-N9831 — OS [18]
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Figure 3b. Long-term study results: BCIRG 006 — OS [19]
Figure 3a. Long-term study results: BCIRG 006 — DFS [19]
Trastuzumab was added into the treatment immediately 
with taxoids (after 4 cycles of anthracyclines) or at the mo-
ment of initiation of adjuvant chemotherapy in the arm 
without anthracyclines (BCIRG 006 study), after 3 AC chemo-
therapy cycles (American trials) or after the completion 
of chemo- and, alternatively, also radiotherapy (the HERA 
study). The above studies did not evaluate the immediate 
combination of trastuzumab with anthracyclines, as such 
combinations were evaluated in the neoadjuvant treatment. 
Currently, in the case of the application of chemotherapy 
with anthracyclines, it is recommended to include trastu-
zumab as late as after the completion of the treatment with 
chemotherapy with anthracyclines. Sequential combination 
is safer with regards to cardiotoxicity than immediate com-
bination. Trastuzumab, however, should be administered 
immediately with taxoids, as the long term study results 
show that such a combination is more beneficial than the 
administration of trastuzumab sequentially after taxoids 
[8, 25, 26]. The exemplary regimens are, for example: 4 × 
AC Æ Pct + T lub Dct + T; 3 × FEC Æ 3 × Dct and, the DCbT 
(TCH) regimen, which was evaluated in the BCIRG 006 study. 
Cardiotoxicity connected with trastuzumab consists 
mostly in cardiac muscle failure and LVEF decrease. These 
adverse events are studied in detail in each study evaluating 
the use of trastuzumab. The Cochrane Collaboration For the 
Cochrane Collaboration meta-analysis proved an increased 
risk of cardiac failure: relative risk (RR) 5.11; p < 0.00001) and 
of LVEF reduction (RR 1.83; p = 0.0008), whereas it must be 
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stressed that for this meta-analysis, the third arm of the 3 
BCIRG 006 was not included [27]. It was numerously proven 
that cardiotoxicity caused by trastuzumab is reversible, pro-
vided that the administration of the drug is discontinued. 
Nevertheless, patients for such treatment must be carefully 
selected, taking into account their history of circulatory dis-
eases and an evaluation of the left ventricle ejection fraction. 
It should be stressed that the adjuvant treatment of patients 
with HER2-positive breast cancer with chemotherapy with-
out anthracyclines has a documented value [14].
The authors of the meta-analysis from 2011 observed 
more frequent incidence of breast cancer recurrence in the 
central nervous system in patients treated with trastuzumab, 
which is probably related to the life prolongation in this 
group of patients [28].
The majority of the randomised clinical studies do not in-
clude the patients with very early breast cancer, in particular 
those with so-called “small nodules”, whose size, in patho-
morphological evaluation do not exceed 1 cm (pT1a/bN0). 
Although retrospective data suggest that the patients with 
the advancement stage pT1a/bN0 benefit from adjuvant 
therapy with trastuzumab, these data are still insufficient 
[29]. In the above studies, such patients made up a small 
share of the population and the results of the studies in such 
a sub-population were usually not reported. The patients 
with HER2-positive breast cancer in the pT1a/bN0M0 stage, 
however, have a higher recurrence risk and shorter survival 
than the patients with HER2-negative breast cancer with the 
same advancement stage; this may suggest that in this case 
the cancer biology may be more significant than the tumour 
size and thus the cancer biology should be the factor that 
determines the treatment choice [30, 31].
Conclusions 
The use of trastuzumab in the adjuvant treatment of 
patients with early HER2-positive breast cancer, decreases 
the risk of recurrence and has a positive influence on life 
prolongation. The results of the discussed studies, published 
more than 10 years ago, in spite of some controversies con-
cerning the optimum regimen and duration of treatment, 
almost immediately provided the grounds for changes in 
the standard treatment. The years of studies on the use of 
trastuzumab helped to reduce doubts concerning the dura-
tion of treatment and the optimum method of combining 
trastuzumab with chemotherapy and provided thorough 
knowledge bases about the drug’s safety. In accordance 
with the current state of knowledge, adjuvant therapy with 
trastuzumab should last one year (or until the recurrence 
of the disease, if the recurrence occurs earlier). Trastuzum-
ab should be administered together with taxoids, as such 
a combination is more effective than its administration after 
taxoids, and there are no medical contraindications for im-
mediate administration of trastuzumab with post-operative 
radiotherapy. In order to reduce cardiotoxicity, it seems 
worthwhile to consider chemotherapy excluding anthra-
cyclines (DCbT) also in patients with pN+.
Many years of observation of patients with HER2-pos-
itive breast cancer showed that the introduction of trastu-
zumab to clinical practice changed the natural course of 
HER2-positive early breast cancer and the benefits from the 
treatment continue for many years.
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